Shifa Precision

Shifa Precision is a biotechnology company focused on the discovery and development of oral small molecule drugs for the treatment of cardiovascular and metabolic diseases. The company's lead program is a first-in-class oral PCSK9 inhibitor designed to lower LDL cholesterol levels, offering a more convenient alternative to existing injectable therapies like monoclonal antibodies. Shifa utilizes a proprietary drug discovery platform to identify small molecules that disrupt protein-protein interactions. Their pipeline primarily targets hypercholesterolemia and related atherosclerotic cardiovascular diseases. Headquartered in Pennsylvania, the company has received significant support from federal grants and regional venture partners. Their lead candidate, P-21, has shown promising results in preclinical studies and is being advanced toward clinical trials.